LIXTE (LIXT) CFO receives 50,000 RSU award as performance grant

Rhea-AI Filing Summary

Stazzone Peter reported acquisition or exercise transactions in this Form 4 filing.

LIXTE Biotechnology Holdings, Inc. reported that its Chief Financial Officer, Peter Stazzone, received an equity award of 50,000 shares of common stock on a grant or award basis, at a price of $0.00 per share. This award corresponds to 50,000 restricted share units (RSUs) that vest into one share of common stock each.

The footnotes state that these 50,000 RSUs vested after the achievement of performance conditions in the RSU agreement under the company’s 2020 Stock Incentive Plan. Following this award, Column 5 of the Form 4 reflects a total of 100,000 RSUs attributed to the reporting person, including the 50,000 newly awarded RSUs and 50,000 previously held RSUs, all of which have vested.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stazzone Peter

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	50,000	$0.00	--

Holdings After Transaction: Common Stock — 100,000 shares (Direct, null)

Footnotes (1)

1. The reported transaction involved the Reporting Person's receipt of 50,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 50,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied. The total reported in Column 5 includes (i) the 50,000 newly awarded RSUs, and (ii) 50,000 RSUs, all of which have vested.

Key Figures

RSUs granted: 50,000 RSUs Price per share: $0.00 per share Total RSUs after transaction: 100,000 RSUs +1 more

4 metrics

RSUs granted 50,000 RSUs Award of restricted share units to CFO tied to performance

Price per share $0.00 per share Grant or award acquisition of common stock

Total RSUs after transaction 100,000 RSUs Column 5 total including new and prior RSUs, all vested

Transaction date July 1, 2026 Date of reported RSU grant/acquisition

Key Terms

restricted share units ("RSUs"), 2020 Stock Incentive Plan, performance conditions, contingent right

4 terms

restricted share units ("RSUs") financial

"The reported transaction involved the Reporting Person's receipt of 50,000 restricted share units ("RSUs")."

2020 Stock Incentive Plan financial

"The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan."

performance conditions financial

"The 50,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied."

contingent right financial

"Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:19 PM Accepted by SEC EDGAR 07/02/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stazzone Peter

(Last) (First) (Middle)

433 PLAZA REAL, SUITE 275

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A		50,000(1)	A	$0	100,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involved the Reporting Person's receipt of 50,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 50,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

2. The total reported in Column 5 includes (i) the 50,000 newly awarded RSUs, and (ii) 50,000 RSUs, all of which have vested.

	/s/ Peter Stazzone	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did LIXT’s CFO report on this Form 4?

LIXTE’s CFO Peter Stazzone reported an acquisition of 50,000 shares of common stock via a grant of restricted share units (RSUs) at $0.00 per share, under the company’s 2020 Stock Incentive Plan, tied to satisfied performance conditions.

How many LIXT RSUs does the CFO hold after this reported grant?

After the reported grant, Column 5 shows 100,000 restricted share units attributed to the CFO. This total includes 50,000 newly awarded RSUs and 50,000 previously held RSUs, with the footnotes stating that all of these RSUs have vested.

What are the vesting conditions for the LIXT CFO’s 50,000 RSUs?

The 50,000 RSUs vested upon achievement of performance conditions in the CFO’s RSU agreement. The footnotes explain these RSUs were granted under Lixte Biotechnology Holdings, Inc.’s 2020 Stock Incentive Plan and required continued service plus specified performance goals.

Did the LIXT CFO pay cash for the 50,000 awarded shares?

The Form 4 reports a transaction price of $0.00 per share for the 50,000 common shares. This indicates the shares were received as a grant or award of restricted share units rather than purchased in the open market for cash consideration.

Are all of the LIXT CFO’s reported RSUs vested according to the filing?

The footnotes state that the 50,000 RSUs tied to this transaction have vested after meeting performance conditions. They also note the 100,000 total in Column 5 includes 50,000 newly awarded RSUs and 50,000 RSUs, all of which have vested under the plan.